BRAF is a proto-oncogene mutated in many types of cancers. The majority of BRAF mutations described occur at codon 600. Codon 600 mutations are present in between 40-60% of malignant melanomas. Melanomas with a mutation at codon 600 of BRAF show a higher likelihood of response to treatment with BRAF inhibitors e.g. Vemurafenib. Somatic mutations in NRAS codons 12, 13 or 61 have been found in ~13–25% of all malignant melanomas and their presence or absence can be used to guide appropriate therapy. Somatic mutations in KIT have been found in 2–8% of all malignant melanoma.
Please refer to the National Genomic Test Directory for Cancer here.
Targeted salvage pathway 7 calendar days
Melanoma panel 14 calendar days
Please refer to our Sample Requirements section before sending any samples to us for testing.